Eli Lilly to work with Sanford-Burnham on autoimmune diseases

Eli Lilly ($LLY) has signed up to collaborate with researchers at Sanford-Burnham on a new generation of immunological drugs for diseases like lupus, Sjögren's syndrome, inflammatory bowel disease and other autoimmune disorders. The pact builds on a big commitment that Lilly has in immunology, with 7 programs in the pipeline for psoriasis, rheumatoid arthritis, lupus and inflammatory bowel disease. Sanford-Burnham's work in this area "focuses on cell communication pathways that control the development of lymphocytes, innate and adaptive immune responses, and inflammation." Release

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.